Healthcare Industry News: HSMN NewsFeed

Biopharmaceuticals FDA

 News Release - August 23, 2017

Stryker provides an update regarding Sage warning letter and revised financial guidance

Kalamazoo, Michigan – August 23, 2017 -- (Healthcare Sales & Marketing Network) -- Stryker Corporation (NYSE: SYK) announced today that the company has informed the U.S. Food and Drug Administration (FDA) of a voluntary product recall involving specific lots of Oral Care products sold through the company’s Sage Products business unit (Sage). The recalled products contain Oral Care solutions manufactured for Sage by a third-party supplier and were distributed between July 2015 and August 2017. The recall is being initiated due to a potential for cross-contamination of Oral Care solutions manufactured by the third party on equipment shared with non-pharmaceutical products, as stated in a Warning Letter from FDA dated July 17, 2017. To date, Stryker has not been made aware of any serious adverse events associated with the Oral Care products recall. However, there have been some reports of minor irritation and allergic reaction. Stryker has discontinued business with the third-party supplier and all Oral Care solutions are being manufactured in-house by Sage. Stryker expects to resume shipping Oral Care products in September and anticipates a return to full supply capacity by year end.

Additionally, the FDA Warning Letter sets forth concerns regarding microbiological testing methods used for all products containing solutions sold by Sage. These include Oral Care solutions in the recalled products and solutions contained in cloth-based products manufactured by Sage. FDA indicated that products must now be tested using a verified compendial microbiological method, a growth-based method that requires more time to complete than the one previously used at Sage. Both methods can detect the presence of microorganisms, while the compendial method provides additional information about the type and number of microorganisms. As a result, in August, Stryker placed cloth-based products, which represents approximately 50% of Sage’s revenue, on a temporary ship hold until they are tested using this method. Stryker anticipates it will resume shipping products manufactured by Sage and tested under the compendial method in September, and anticipates a return to full supply capacity by year end.

Based on the estimated impact to sales and operating income, Stryker now expects full year organic sales growth and adjusted net earnings per diluted share to be at the lower end of its previously stated range of 6.5% to 7.0% and $6.45-$6.55, respectively. For the third quarter, Stryker anticipates that adjusted net earnings per diluted share will be at the lower end of its previously stated range of $1.50-$1.55. Our third quarter range does not assume any dilution related to the pending acquisition of Novadaq; based on a September 30, 2017 close date for Novadaq, the dilution is expected at approximately $0.03-$0.05 in 2017.

Forward-looking statements

This press release contains information that includes or is based on forward-looking statements within the meaning of the federal securities law that are subject to various risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements. Such factors include, but are not limited to: unanticipated issues in addressing in a timely manner the Sage product-related issues discussed above; weakening of economic conditions that could adversely affect the level of demand for our products; pricing pressures generally, including cost-containment measures that could adversely affect the price of or demand for our products; changes in foreign exchange markets; legislative and regulatory actions; unanticipated issues arising in connection with clinical studies and otherwise that affect U.S. Food and Drug Administration approval of new products; potential supply disruptions; changes in reimbursement levels from third-party payors; a significant increase in product liability claims; the ultimate total cost with respect to the Rejuvenate and ABG II matter; the impact of investigative and legal proceedings and compliance risks; resolution of tax audits; the impact of the federal legislation to reform the United States healthcare system; changes in financial markets; changes in the competitive environment; our ability to integrate acquisitions; and our ability to realize anticipated cost savings. Additional information concerning these and other factors is contained in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Stryker is one of the world's leading medical technology companies and, together with our customers, we are driven to make healthcare better. The Company offers a diverse array of innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes. Stryker is active in over 100 countries around the world. Please contact us for more information at www.stryker.com.


Source: Stryker

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



RepFinder 2 - Find Great Medical Independent Sales Reps without recruiter fees.RepFinder 2 - available on the Apple App Store for iPhone and iPad.